Androgen Receptor Variants and Prostate Cancer in Humanized AR Mice

Overview

Journal J Steroid Biochem Mol Biol

Specialties Biochemistry
Molecular Biology

Date 2007 Oct 16

PMID 17936615

Citations 6

Authors

Diane M Robins

Megan A Albertelli

Orla A OMahony

Affiliations

Soon will be listed here.

Abstract

Androgen, acting via the androgen receptor (AR), is central to male development, differentiation and hormone-dependent diseases such as prostate cancer. AR is actively involved in the initiation of prostate cancer, the transition to androgen independence, and many mechanisms of resistance to therapy. To examine genetic variation of AR in cancer, we created mice by germ-line gene targeting in which human AR sequence replaces that of the mouse. Since shorter length of a polymorphic N-terminal glutamine (Q) tract has been linked to prostate cancer risk, we introduced alleles with 12, 21 or 48 Qs to test this association. The three "humanized" AR mouse strains (h/mAR) are normal physiologically, as well as by cellular and molecular criteria, although slight differences are detected in AR target gene expression, correlating inversely with Q tract length. However, distinct allele-dependent differences in tumorigenesis are evident when these mice are crossed to a transgenic prostate cancer model. Remarkably, Q tract variation also differentially impacts disease progression following androgen depletion. This finding emphasizes the importance of AR function in androgen-independent as well as androgen-dependent disease. These mice provide a novel genetic paradigm in which to dissect opposing functions of AR in tumor suppression versus oncogenesis.

Citing Articles

Selective modulation of the androgen receptor AF2 domain rescues degeneration in spinal bulbar muscular atrophy.

Badders N, Korff A, Miranda H, Vuppala P, Smith R, Winborn B Nat Med. 2018; 24(4):427-437.

PMID: 29505030 PMC: 5975249. DOI: 10.1038/nm.4500.

Polymorphisms in sex steroid receptors: From gene sequence to behavior.

Maney D Front Neuroendocrinol. 2017; 47:47-65.

PMID: 28705582 PMC: 6312198. DOI: 10.1016/j.yfrne.2017.07.003.

Targeting alternative sites on the androgen receptor to treat castration-resistant prostate cancer.

Lallous N, Dalal K, Cherkasov A, Rennie P Int J Mol Sci. 2013; 14(6):12496-519.

PMID: 23771019 PMC: 3709796. DOI: 10.3390/ijms140612496.

Androgen receptor gene polymorphisms and alterations in prostate cancer: of humanized mice and men.

Robins D Mol Cell Endocrinol. 2011; 352(1-2):26-33.

PMID: 21689727 PMC: 3188356. DOI: 10.1016/j.mce.2011.06.003.

Corepressor effect on androgen receptor activity varies with the length of the CAG encoded polyglutamine repeat and is dependent on receptor/corepressor ratio in prostate cancer cells.

Buchanan G, Need E, Barrett J, Bianco-Miotto T, Thompson V, Butler L Mol Cell Endocrinol. 2011; 342(1-2):20-31.

PMID: 21664238 PMC: 3314496. DOI: 10.1016/j.mce.2011.05.023.

References

Roy-Burman P, Tindall D, Robins D, Greenberg N, Hendrix M, Mohla S . Androgens and prostate cancer: are the descriptors valid?. Cancer Biol Ther. 2005; 4(1):4-5. DOI: 10.4161/cbt.4.1.1563. View

Chamberlain N, Driver E, Miesfeld R . The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res. 1994; 22(15):3181-6. PMC: 310294. DOI: 10.1093/nar/22.15.3181. View

Kaplan-Lefko P, Chen T, Ittmann M, Barrios R, Ayala G, Huss W . Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate. 2003; 55(3):219-37. DOI: 10.1002/pros.10215. View

July L, Akbari M, Zellweger T, Jones E, Goldenberg S, Gleave M . Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate. 2002; 50(3):179-88. DOI: 10.1002/pros.10047. View

Feinberg A, Ohlsson R, Henikoff S . The epigenetic progenitor origin of human cancer. Nat Rev Genet. 2005; 7(1):21-33. DOI: 10.1038/nrg1748. View

He B, Wilson E . The NH(2)-terminal and carboxyl-terminal interaction in the human androgen receptor. Mol Genet Metab. 2002; 75(4):293-8. DOI: 10.1016/S1096-7192(02)00009-4. View

Han G, Buchanan G, Ittmann M, Harris J, Yu X, DeMayo F . Mutation of the androgen receptor causes oncogenic transformation of the prostate. Proc Natl Acad Sci U S A. 2005; 102(4):1151-6. PMC: 544619. DOI: 10.1073/pnas.0408925102. View

Gingrich J, Barrios R, Kattan M, Nahm H, Finegold M, Greenberg N . Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res. 1997; 57(21):4687-91. View

Choong C, Kemppainen J, Zhou Z, Wilson E . Reduced androgen receptor gene expression with first exon CAG repeat expansion. Mol Endocrinol. 1996; 10(12):1527-35. DOI: 10.1210/mend.10.12.8961263. View

10.

La Spada A, Wilson E, Lubahn D, Harding A, Fischbeck K . Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature. 1991; 352(6330):77-9. DOI: 10.1038/352077a0. View

11.

Trotman L, Niki M, Dotan Z, Koutcher J, Di Cristofano A, Xiao A . Pten dose dictates cancer progression in the prostate. PLoS Biol. 2003; 1(3):E59. PMC: 270016. DOI: 10.1371/journal.pbio.0000059. View

12.

Albertelli M, Scheller A, Brogley M, Robins D . Replacing the mouse androgen receptor with human alleles demonstrates glutamine tract length-dependent effects on physiology and tumorigenesis in mice. Mol Endocrinol. 2006; 20(6):1248-60. DOI: 10.1210/me.2006-0021. View

13.

Zitzmann M, Nieschlag E . The CAG repeat polymorphism within the androgen receptor gene and maleness. Int J Androl. 2003; 26(2):76-83. DOI: 10.1046/j.1365-2605.2003.00393.x. View

14.

Mangelsdorf D, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K . The nuclear receptor superfamily: the second decade. Cell. 1995; 83(6):835-9. PMC: 6159888. DOI: 10.1016/0092-8674(95)90199-x. View

15.

Buchanan G, Greenberg N, Scher H, Harris J, Marshall V, Tilley W . Collocation of androgen receptor gene mutations in prostate cancer. Clin Cancer Res. 2001; 7(5):1273-81. View

16.

Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C . In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet. 1995; 9(4):401-6. DOI: 10.1038/ng0495-401. View

17.

Han G, Foster B, Mistry S, Buchanan G, Harris J, Tilley W . Hormone status selects for spontaneous somatic androgen receptor variants that demonstrate specific ligand and cofactor dependent activities in autochthonous prostate cancer. J Biol Chem. 2000; 276(14):11204-13. DOI: 10.1074/jbc.M008207200. View

18.

Johnson M, Hernandez I, Wei Y, Greenberg N . Isolation and characterization of mouse probasin: An androgen-regulated protein specifically expressed in the differentiated prostate. Prostate. 2000; 43(4):255-62. DOI: 10.1002/1097-0045(20000601)43:4<255::aid-pros4>3.0.co;2-m. View

19.

Lange E, Chen H, Brierley K, Livermore H, Wojno K, Langefeld C . The polymorphic exon 1 androgen receptor CAG repeat in men with a potential inherited predisposition to prostate cancer. Cancer Epidemiol Biomarkers Prev. 2000; 9(4):439-42. View

20.

Raffo A, Perlman H, Chen M, Day M, Streitman J, Buttyan R . Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res. 1995; 55(19):4438-45. View